C1s, cleaves C4 and C2 to initiate the classical complement cascade. In CAD, autoantibodies trigger complement-mediated destruction of red blood cells. Sutimlimab's inhibition of C1s prevents this pathway, rapidly reducing hemolysis, improving anemia, and alleviating fatigue without broadly suppressing other complement pathways (e.g., alternative or lectin).